{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:49:36Z","timestamp":1791409776335,"version":"4.3.3"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhep.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:12:08Z","timestamp":1781935928000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rifaximin and the DCA\u2013serotonin axis in cirrhotic portal hypertension: How much of the benefit is bile-acid specific?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-7890","authenticated-orcid":false,"given":"Chetan R.","family":"Kalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3860-2512","authenticated-orcid":false,"given":"Piyush","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2026.06.018_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2026.05.001","article-title":"Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid","volume":"85","author":"Xiong","year":"2026","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.018_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.018_bib3","doi-asserted-by":"crossref","first-page":"G449","DOI":"10.1152\/ajpgi.00199.2012","article-title":"Animal models of chronic liver diseases","volume":"304","author":"Liu","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.jhep.2026.06.018_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:55:49Z","timestamp":1791406549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826026504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":4,"alternative-id":["S0168827826026504"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifaximin and the DCA\u2013serotonin axis in cirrhotic portal hypertension: How much of the benefit is bile-acid specific?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}